GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition

BACKGROUND: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GNS561, a new lysosomotropic molecule with high live...

Descripción completa

Detalles Bibliográficos
Autores principales: Bestion, Eloïne, Jilkova, Zuzana Macek, Mège, Jean-Louis, Novello, Marie, Kurma, Keerthi, Pour, Seyedeh Tayebeh Ahmad, Lalmanach, Gilles, Vanderlynden, Lise, Fizanne, Lionel, Bassissi, Firas, Rachid, Madani, Tracz, Jennifer, Boursier, Jérôme, Courcambeck, Jérôme, Serdjebi, Cindy, Ansaldi, Christelle, Decaens, Thomas, Halfon, Philippe, Brun, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366401/
https://www.ncbi.nlm.nih.gov/pubmed/32728410
http://dx.doi.org/10.1177/2040622320942042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366401/
https://www.ncbi.nlm.nih.gov/pubmed/32728410
http://dx.doi.org/10.1177/2040622320942042

Ejemplares similares